FDA CDC News
FDA Works to Further Improve Nutrition, Reduce Diet-Related Chronic Disease with Dietary Guidance Statements on Food Labels
“Diet-related chronic diseases, are the leading causes of death and disability in the U.S.
- Share
- Tweet
- FDA Works to Further Improve Nutrition, Reduce Diet-Related Chronic Disease with Dietary Guidance Statements on Food Labels https://stmdailynews.com/fda-works-to-further-improve-nutrition-reduce-diet-related-chronic-disease-with-dietary-guidance-statements-on-food-labels/">
Last Updated on March 25, 2023 by Daily News Staff
The U.S. Food and Drug Administration today issued draft guidance that provides food manufacturers with recommendations on how and when to use Dietary Guidance Statements on the label of food products to ensure the label statements promote good nutrition, provide greater consistency in labeling, and assist consumers in making informed choices. This guidance is part of the FDA’s overall goal to help reduce the burden of chronic disease and advance health equity through improved nutrition.
“Diet-related chronic diseases, are the leading causes of death and disability in the U.S. and disproportionally impact communities of color and people living in rural areas,” said FDA Commissioner Robert M. Califf, M.D. “The FDA is committed to being a part of the solution to improve the health of millions of Americans. Today’s action is another step towards helping consumers make informed choices about the foods they eat.”
Today’s eating patterns in the U.S. do not align with current federal dietary recommendations, which focus on the entirety of the diet and how foods and beverages work together to affect health. Dietary Guidance Statements are statements in food labeling which are based on key recommendations from consensus reports, such as the Dietary Guidelines for Americans, 2020-2025, that discuss how a food or food group can be a part of a nutritious dietary pattern. The statements may include symbols or pictures that convey to consumers that a food or a food group may contribute to, or help maintain, a nutritious dietary pattern.
Examples of Dietary Guidance Statements include: “Make half your grains whole grain,” and “Eat leafy green vegetables as part of a nutritious dietary patten.” The draft guidance provides the agency’s thinking about the use of such statements, including recommendations that products contain a meaningful amount of the food, or category of foods, that is the subject of the statement, and that they also not exceed certain amounts of saturated fat, sodium and added sugars. The recommendations in the guidance can enhance consistency in the use of such statements and consumer understanding as well as facilitate industry innovation toward healthier foods. Like other labeling statements and claims, Dietary Guidance Statements act as quick signals on food packages to help consumers better understand nutrition information and make healthier food choices.
Today’s action is part of the FDA’s overall nutrition initiatives, which include empowering consumers by providing more informative labeling and education, including tailored messages for various audiences to help consumers identify foods that can contribute to healthier diets. It is also part of the Biden-Harris Administration’s National Strategy on Hunger, Nutrition, and Health, which provides a roadmap of actions the federal government will take to end hunger and reduce diet-related diseases by 2030 – all while reducing disparities. Complementing today’s guidance and the National Strategy, the FDA issued a proposed rule in September 2022 to update the definition of “healthy” on food labels and help consumers more easily identify healthy food choices. The agency’s work also supports the Biden-Harris Administration’s White House Challenge to End Hunger and Build Healthy Communities, a nationwide call-to-action to stakeholders across all of society to make bold commitments to advance the Strategy’s goals. The
Challenge builds on the success of the $8 billion package of private and public sector commitments that the Administration announced as part of the historic conference.
Another priority of the FDA’s nutrition efforts is to create a healthier food supply for all. In October 2021, the FDA issued final guidance for the food industry that provided voluntary, short-term sodium reduction targets for a broad range of processed, packaged and prepared foods to help reduce the amount of sodium in the U.S. food supply.
“In addition to the Dietary Guidance Statements draft guidance, reducing sodium intake and updating the definition of “healthy” are two other examples of how the agency is showing its commitment to fostering a healthier food supply for all and empowering consumers with more informative and accessible labeling to choose healthier diets,” said Susan Mayne, Ph.D., director of the FDA’s Center for Food Safety and Applied Nutrition. “We are making great strides in our nutrition initiatives in order to improve the health and wellness of our nation.”
The FDA remains committed to doing its part in the all-of-government approach to improving nutrition, which can have a lasting generational impact on reducing chronic diseases and advancing health equity. The agency is moving forward with additional nutrition and labeling priorities, including exploring a “front-of-pack” labeling initiative and recommendations for nutrition labeling for online grocery shopping sites. Additionally, the FDA will begin assessing further strategies to reduce added sugar consumption, which includes collaborating with others in the U.S. Department of Health and Human Services and the U.S. Department of Agriculture to hold a public meeting regarding future steps the federal government could take to reduce intake of added sugars.
Related Information
- Draft Guidance: Questions and Answers About Dietary Guidance Statements in Food Labeling: Guidance for Industry
- Constituent Update: FDA Issues Draft Guidance on Dietary Guidance Statements on Food Labels
- Press Release: FDA Proposes Updated Definition of ‘Healthy’ Claim on Food Packages to Help Improve Diet, Reduce Chronic Disease
- Press Release: To Improve Nutrition and Reduce the Burden of Disease, FDA Issues Food Industry Guidance for Voluntarily Reducing Sodium in Processed and Packaged Foods
- FDA’s Nutrition Initiatives
Source: FDA
Lifestyle
Reclassification of marijuana opens doors for much‑needed medical research into the benefits and risks of the drug
The DOJ’s move to reclassify medical marijuana as Schedule III could unlock long-blocked cannabis research—while raising new questions about safety, regulation, and risk.
Last Updated on June 2, 2026 by Daily News Staff
Carey S. Cadieux, Binghamton University, State University of New York
When the U.S. Department of Justice moved to reclassify medical marijuana to a Schedule III drug on April 23, 2026, it set the stage for a vast amount of medical research that has been hobbled for decades by its more restrictive Schedule I classification.
The Justice Department also called for an expedited federal rescheduling process, with proceedings expected to begin in late June 2026, but for now cannabis at the federal level remains a Schedule I drug.
I’m an associate professor of nursing and I edited a textbook for nurses about providing care with cannabis. Cannabis is the umbrella term for the plant genus that includes both marijuana and hemp – two varieties of the same plant distinguished primarily by their content of THC, one of the active components of cannabis.
Moving cannabis to a Schedule III drug ushers in the end of the cannabis prohibition era and the beginning of the regulation era, potentially creating promising opportunities around research and new therapeutics.
How are drugs regulated by ‘schedule’?
The Controlled Substances Act of 1970 categorizes all substances regulated under existing federal law into one of five schedules. The act regulates the manufacturing, importation, possession, use and distribution of substances on each schedule.
Several factors determine schedule placement, including the drug’s medical use, scientific evidence of its benefits and pharmacological effects, patterns and history of abuse, public health risk level, degree of physical or psychological addiction potential, and whether the drug can be used to make another controlled substance.
The Drug Enforcement Administration’s rescheduling of marijuana will move it from its current classification as a Schedule I drug, defined as having a high risk for abuse and no accepted medical use, to a Schedule III drug under the Controlled Substances Act. While still tightly regulated, Schedule III drugs are considered to have moderate to low risk for physical and psychological dependence and to have some medical benefits.
Other Schedule I drugs include heroin, psilocybin, LSD, peyote and MDMA, or ecstasy. These drugs cannot be dispensed or prescribed, with some exceptions. Current Schedule III drugs include ketamine, anabolic steroids, testosterone, products with less than 90 milligrams of codeine per dosage unit and some cannabinoids.
The move to reclassify medical marijuana products as Schedule III drugs applies only to those products certified by state-level medical cannabis programs. All other cannabis products remain a federal Schedule I drug, including those available from states’ recreational cannabis programs.
Impacts of cannabis reclassification
This legal order acknowledges that medical marijuana has some medical value and asserts that it has a lower potential for abuse than under the previous Schedule I classification.
The reclassification also ensures that state-registered medical cannabis patients continue to be permitted to purchase medical cannabis products without changes to their current certification or recommendation.
One of the challenges with this new law is that states have not standardized medical cannabis regulations, and each state will have its own quality and testing standards. In Maine, for instance, medical cannabis is not tested for molds, fungus, heavy metals or pesticides, while recreational cannabis is.
This means that the Schedule III medical cannabis in Maine could be contaminated, while the state’s testing of recreational cannabis makes it much safer to consume.
What are the implications for marijuana research?
For decades, researchers have struggled to conduct high-quality research studies due to their lack of access to the cannabis products that patients actually use and restrictions on their processes.
With the reclassification, researchers who are registered with the DEA to research cannabis will be able to obtain cannabis flower and plant material, as well as manufactured cannabis products, such as tinctures and edibles, directly from state-licensed businesses that are DEA-registered.
This means researchers will no longer need to rely on the federal DEA registry for access to cannabis products for research, which were often inferior in quality and variety in comparison to the everyday products medical cannabis patients typically have access to. Instead, they will be able to study cannabis products that patients use in daily life, such as vapes and various edible products.
This shift in access will now allow researchers to undertake the gold standard of research approaches: the randomized controlled trial.
Randomized controlled trials will help researchers like my colleagues determine how effective cannabis is in treating people with complex medical needs. This includes patients who experience nausea and pain while undergoing cancer treatments, multiple sclerosis patients with severe muscle spasm and stiffness, and chronic pain patients who strive to find relief without using opioids.
Might rescheduling send mixed signals?
Rescheduling may lead people to believe that cannabis is safe for all people to consume.
However, a growing body of research points to possible adverse effects from cannabis use, particularly in vulnerable groups, such as people who are pregnant, adolescents, people with preexisting mental health conditions such as schizophrenia or psychosis, and those with cardiac issues.
Cannabis can also lead to adverse drug interactions. Therefore, medical patients should use it with discretion and under the guidance of a healthcare professional.
For most medical cannabis patients, THC doses should start low and gradually be increased.
Rescheduling will be a big step toward helping researchers build a greatly needed solid body of evidence around both the benefits and potential harms of cannabis. But rescheduling should not be interpreted as a signal that cannabis is harmless.
Carey S. Cadieux, Associate Professor of Nursing, Binghamton University, State University of New York
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Our Lifestyle section on STM Daily News is a hub of inspiration and practical information, offering a range of articles that touch on various aspects of daily life. From tips on family finances to guides for maintaining health and wellness, we strive to empower our readers with knowledge and resources to enhance their lifestyles. Whether you’re seeking outdoor activity ideas, fashion trends, or travel recommendations, our lifestyle section has got you covered. Visit us today at https://stmdailynews.com/category/lifestyle/ and embark on a journey of discovery and self-improvement.
FDA CDC News
Norovirus Cases Continue Spreading Across the U.S. as Health Officials Monitor Outbreaks
Health officials across the United States are monitoring rising norovirus outbreaks linked to schools, cruise ships, healthcare facilities, and contaminated food sources as cases continue spreading nationwide.
Last Updated on May 30, 2026 by Rod Washington
Health officials across the United States are continuing to monitor widespread norovirus activity as outbreaks have been reported in schools, healthcare facilities, cruise ships, restaurants, and community settings nationwide.
Norovirus Outbreaks
According to the Centers for Disease Control and Prevention (CDC), more than 1,190 norovirus outbreaks were reported by participating states between August 2025 and early May 2026. The CDC says the virus remains active in several regions, particularly in the Northeast and Midwest, while cases continue appearing in parts of California and other western states.
Norovirus, often called the “stomach flu” or “winter vomiting bug,” is one of the leading causes of acute gastroenteritis in the United States. The virus spreads rapidly through contaminated food, water, surfaces, and close contact with infected individuals.
Recent outbreaks aboard cruise ships have also gained national attention. The CDC’s Vessel Sanitation Program has tracked multiple gastrointestinal illness outbreaks this year, including incidents involving large numbers of passengers and crew members becoming ill during voyages.
Health experts say symptoms typically appear within 12 to 48 hours after exposure and commonly include:
- Vomiting
- Diarrhea
- Stomach cramps
- Nausea
- Fever and body aches
Most people recover within one to three days, but dehydration can become serious, especially for children, older adults, and individuals with weakened immune systems.
Officials continue emphasizing prevention measures as the best defense against infection. Recommended precautions include washing hands thoroughly with soap and water, disinfecting contaminated surfaces with bleach-based cleaners, properly washing produce, and avoiding food preparation while sick.
Medical experts also note that alcohol-based hand sanitizers are generally less effective against norovirus than traditional handwashing.
While current activity has raised concerns due to the number of outbreaks being reported nationwide, health agencies say norovirus outbreaks remain a seasonal and recurring public health issue rather than a pandemic-level event.
The CDC continues tracking outbreak trends through its NoroSTAT and CaliciNet surveillance systems as health departments nationwide monitor additional cases heading into the summer travel season.
For more public health and breaking news updates, visit STM Daily News.
Sources: CDC Norovirus Updates | CDC NoroSTAT Data Dashboard | CDC Cruise Ship Outbreak Reports
(CDC)
Last Updated on May 6, 2026 by Daily News Staff
Second Nature Brands has issued a voluntary recall for certain 10-ounce pouches of SECOND NATURE KETO CRUNCH SMART MIX™ after discovering the product may contain undeclared cashews, pistachios, and cherries. For anyone with allergies or severe sensitivities—especially to tree nuts like cashews and pistachios—this is a serious safety issue.
The company says the affected product was distributed nationwide, both in retail stores and through online orders.
Why this matters
Undeclared allergens are one of the most urgent types of food safety alerts because consumers rely on labels to avoid ingredients that can trigger reactions. Second Nature Brands warns that people with allergies or severe sensitivity to cashews, pistachios, other tree nuts, or cherries could face serious or life-threatening allergic reactions if they consume the recalled product.
As of the announcement, no illnesses have been reported.
How to identify the recalled product
Check your pantry (and any recent online snack orders) for the following details:
- Product: SECOND NATURE KETO CRUNCH SMART MIX™
- Size: 10-ounce pouch
- UPC: 077034013405
- Best if used by date: 2/12/2027 (printed on the backside of the pouch)
Only pouches with the “Best if used by 2/12/2027” date are included. Other Best if used by dates are not affected, according to the company.
What happened
Second Nature Brands says the recall began after it was discovered that product containing cashews, pistachios, and cherries was placed into packaging that did not disclose those allergens. The company reports that a follow-up investigation indicates the issue was caused by a temporary breakdown in production and packaging processes.
The recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).
What consumers should do right now
If you have the affected product:
- Do not consume it.
- Keep the pouch (and take a photo of the UPC and Best if used by date if helpful).
- Contact Second Nature Brands for a full refund.
Contact information for refunds and questions
Second Nature Brands says consumers can reach them by phone or email:
- Phone: +1.800.651.7263
- Monday–Friday: 8:00 AM–8:00 PM ET
- Saturday–Sunday: 9:00 AM–5:00 PM ET
- Email: recall@secondnaturebrandsus.com
Health & fitness note: “Keto” doesn’t equal “risk-free”
Keto-friendly snacks can be convenient for people managing carbs, training schedules, or busy workdays—but this alert is a reminder that label accuracy is non-negotiable, especially for anyone balancing nutrition goals with medical dietary restrictions.
If you or someone in your household has a tree nut or cherry allergy, consider doing a quick sweep of:
- Snack drawers at home and work
- Gym bags and travel kits
- Recent bulk orders or subscription deliveries
Bottom line
If you have a 10-ounce pouch of SECOND NATURE KETO CRUNCH SMART MIX™ with UPC 077034013405 and Best if used by 2/12/2027, do not eat it. Contact Second Nature Brands for a refund and share the alert with anyone who may have purchased the product—especially those with tree nut or cherry allergies.
Source
Welcome to the Consumer Corner section of STM Daily News, your ultimate destination for savvy shopping and informed decision-making! Dive into a treasure trove of insights and reviews covering everything from the hottest toys that spark joy in your little ones to the latest electronic gadgets that simplify your life. Explore our comprehensive guides on stylish home furnishings, discover smart tips for buying a home or enhancing your living space with creative improvement ideas, and get the lowdown on the best cars through our detailed auto reviews. Whether you’re making a major purchase or simply seeking inspiration, the Consumer Corner is here to empower you every step of the way—unlock the keys to becoming a smarter consumer today!
